Meeting
2018 ASCO Annual Meeting
An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).
Authors
Myung-Ju Ahn
Samsung Medical Center, Seoul, Korea, Republic of (South)
Myung-Ju Ahn , Jang Ho Cho , Jong-Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Keon Uk Park , Eun Joo Kang , Yoon Hee Choi , Ki Hwan Kim , Ho Jung An , Hyun Woo Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03424759
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9050)
DOI
10.1200/JCO.2018.36.15_suppl.9050
Abstract #
9050
Poster Bd #
373
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
First Author: Yusuke Okuma
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2022 ASCO Annual Meeting
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
First Author: Hiroshige Yoshioka
Poster
2021 ASCO Annual Meeting
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
First Author: Chao Lyu